Mesoblast Ltd ADRMSB
Price$14.32

Outlook & Key Dates

Estimates, guidance, catalysts, and upcoming events

Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
As of 18 Aug 2026
FY EPS (est.)
-$0.46next fiscal year
As of 18 Aug 2026
Monitoring Framework
Key Performance Indicators
Ryoncil Net Revenue Quarterly30.3MTarget: 110000000 to 120000000
Chronic Low Back Pain Confirmatory Phase 3 Trial Enrollment Annually300.0
Watch Items
  • Revascor BLA Filing for LVAD IndicationTrigger: Completion of CMC and potency assay alignment with FDAAction: Transition from accelerated to full BLA filing
  • Adult SR-aGvHD Phase 3 Trial InitiationTrigger: Central IRB approvalAction: Initiate pivotal study in partnership with BMT CTN
Sign in / Sign up to read more

Research as of 20 Jun 2026

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.